Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1994 1
1995 1
1997 5
1998 1
1999 3
2000 2
2001 1
2002 2
2003 6
2004 3
2005 3
2006 5
2007 10
2008 10
2009 17
2010 15
2011 16
2012 19
2013 24
2014 35
2015 24
2016 17
2017 22
2018 21
2019 33
2020 25
2021 26
2022 19
Text availability
Article attribute
Article type
Publication date

Search Results

307 results
Results by year
Filters applied: . Clear all
Page 1
Cilastatin Ameliorates Rhabdomyolysis-induced AKI in Mice.
Matsushita K, Mori K, Saritas T, Eiwaz MB, Funahashi Y, Nickerson MN, Hebert JF, Munhall AC, McCormick JA, Yanagita M, Hutchens MP. Matsushita K, et al. Among authors: funahashi y. J Am Soc Nephrol. 2021 Oct;32(10):2579-2594. doi: 10.1681/ASN.2020030263. Epub 2021 Aug 2. J Am Soc Nephrol. 2021. PMID: 34341182 Free PMC article.
Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies.
Adachi Y, Kamiyama H, Ichikawa K, Fukushima S, Ozawa Y, Yamaguchi S, Goda S, Kimura T, Kodama K, Matsuki M, Miyano SW, Yokoi A, Kato Y, Funahashi Y. Adachi Y, et al. Among authors: funahashi y. Cancer Res. 2022 Jan 15;82(2):292-306. doi: 10.1158/0008-5472.CAN-20-2426. Epub 2021 Nov 9. Cancer Res. 2022. PMID: 34753772
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.
Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K, Ito J, Tachino S, Hori Y, Matsuki M, Matsuoka Y, Ghosh S, Kitano H, Nomoto K, Matsui J, Funahashi Y. Kato Y, et al. Among authors: funahashi y. PLoS One. 2019 Feb 27;14(2):e0212513. doi: 10.1371/journal.pone.0212513. eCollection 2019. PLoS One. 2019. PMID: 30811474 Free PMC article.
E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.
Yamada K, Hori Y, Inoue S, Yamamoto Y, Iso K, Kamiyama H, Yamaguchi A, Kimura T, Uesugi M, Ito J, Matsuki M, Nakamoto K, Harada H, Yoneda N, Takemura A, Kushida I, Wakayama N, Kubara K, Kato Y, Semba T, Yokoi A, Matsukura M, Odagami T, Iwata M, Tsuruoka A, Uenaka T, Matsui J, Matsushima T, Nomoto K, Kouji H, Owa T, Funahashi Y, Ozawa Y. Yamada K, et al. Among authors: funahashi y. Cancer Res. 2021 Feb 15;81(4):1052-1062. doi: 10.1158/0008-5472.CAN-20-0782. Epub 2021 Jan 6. Cancer Res. 2021. PMID: 33408116
Neuronal polarization.
Takano T, Xu C, Funahashi Y, Namba T, Kaibuchi K. Takano T, et al. Among authors: funahashi y. Development. 2015 Jun 15;142(12):2088-93. doi: 10.1242/dev.114454. Development. 2015. PMID: 26081570 Review.
Second-line lenvatinib in patients with recurrent endometrial cancer.
Vergote I, Powell MA, Teneriello MG, Miller DS, Garcia AA, Mikheeva ON, Bidzinski M, Cebotaru CL, Dutcus CE, Ren M, Kadowaki T, Funahashi Y, Penson RT. Vergote I, et al. Among authors: funahashi y. Gynecol Oncol. 2020 Mar;156(3):575-582. doi: 10.1016/j.ygyno.2019.12.039. Epub 2020 Jan 17. Gynecol Oncol. 2020. PMID: 31955859 Free article. Clinical Trial.
307 results